Condition: Staphylococcus Aureus Bacteremia · Staphylococcus Aureus Septicemia · Staphylococcal Sepsis · Sponsor: Todd C. Lee MD MPH FIDSA
There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
This description comes directly from the study's public registry record.
Lina Petrella · 514-934-1934 · lina.petrella@muhc.mcgill.ca
Always discuss trial participation with your own doctor first.
| Foothills Medical Centre | Calgary, Alberta, Canada | Recruiting |
| Hamilton Health Sciences (Hamilton General Hospital and Juravinski Hospital) | Hamilton, Ontario, Canada | Recruiting |
| Niagara Health - St. Catharines site | Saint Catharines, Ontario, Canada | Recruiting |
| Hospital de la Cité de la Sante | Laval, Quebec, Canada | Recruiting |
| Jewish General Hospital | Montreal, Quebec, Canada | Recruiting |
| McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04886284